GALDERMA Committed to the future of Dermatology Read more ...
Talent Working at GaldermaRead more ...
FOCUSED Patients at the heart of everything we doRead more ...
PARTNER With Healthcare Professionals around the WorldRead more ...
You are here »
About Galderma » Company History
Dermatology company Galderma’s detailed timeline:
Acquisition of Swiss company Spirig AG, maker of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.
Galderma defines its new 3-business-strategy and a new ambition statement.
Opening of a new affiliate in China.
Cetaphil Dermacontrol is launched in 6 countries.
Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Launch of Cetaphil Restoraderm.
Plant extensions in France and Canada. Differin Lotion 0.1% (acne) launch in the United States.
Galderma hits the 1 billion mark in sales.
Launch of Azzalure (glabellar lines) and Oracea in Europe.
Vectical (psoriasis) launch in the United-States.
Epiduo (acne) launch.
Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea).
Launch of Differin 0.1% in Japan.
Licensing agreements for abotulinum toxin type A andPliaglis (topical anesthetic).
Differin 0.3% launch.
Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.
Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).
Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.
Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US.
Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.
Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment).
Launch of Clindagel (anti-acne).
The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).
Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.
Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.
Acquisition of Basotherm, a subsidiary of Boehringer.
Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.
Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.
Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.
Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.
Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.
Galderma’s firstaffiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.
Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.
L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.
Nestlé acquires Alcon to strengthen its presence in the North Americanmarket.
Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
Creation of the Owen dermatology company in Dallas, Texas, USA
Discover more about Galderma, a dermatology company providing dermatology solutions and aesthetic and corrective products internationally.
Growing a responsible dermatological community
Discover some of the positive initiatives we are involved in across the world
We are committed
Avenue Gratta-Paille 2
CH - 1018 Lausanne